<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011374</url>
  </required_header>
  <id_info>
    <org_study_id>FVF4638s</org_study_id>
    <nct_id>NCT01011374</nct_id>
  </id_info>
  <brief_title>Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion</brief_title>
  <official_title>Impact of Lucentis on Psychological Morbidity in Patients With Macular Edema and Neovascularization Secondary to Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Associates of Cleveland, Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Retina Associates of Cleveland, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center, non-randomized clinical study on the impact of&#xD;
      intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning&#xD;
      and emotional well-being in subjects with central or branch retinal vein occlusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measures are changes in the VFQ-25, GHQ-12, and PHQ-9 survey scores from baseline through 24 weeks.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome measures are change in macular edema measured by OCT and estimated by central retinal thickening and correlations between change in visual acuity, depression, and retinal findings such as neovascularization, rubeosis, and perfusion.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Venous Retinal Branch Occlusion</condition>
  <condition>Central Retinal Vein Occlusion</condition>
  <condition>Retinal Vein Occlusion</condition>
  <condition>Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab (Lucentis)</intervention_name>
    <description>0.5 mg, administered intravitreally every 4 weeks</description>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent and comply with study assessments for the&#xD;
             full duration of the study&#xD;
&#xD;
          -  Evidence of central retinal vein occlusion, defined as documented retinal hemorrhage&#xD;
             into all four quadrants with dilated veins, or branch retinal vein occlusion, as&#xD;
             documented on clinical exam&#xD;
&#xD;
          -  Age 18 years or over&#xD;
&#xD;
          -  Central macular edema on clinical exam as well as imaging with a central thickness of&#xD;
             â‰¥ 250 microns&#xD;
&#xD;
          -  Visual acuity ranging from 20/8000 to 20/40&#xD;
&#xD;
          -  Media clarity and patient cooperation sufficient to allow adequate testing utilizing&#xD;
             OCT and FA&#xD;
&#xD;
          -  No previous treatment that might compromise or confound assessment of the study&#xD;
             outcomes&#xD;
&#xD;
          -  Ability to speak and read English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute illness or cognitive or other impairment that, in the opinion of the&#xD;
             investigator, would interfere with study requirements&#xD;
&#xD;
          -  Concurrent ocular conditions likely to significantly compromise vision and contribute&#xD;
             the macular compromise&#xD;
&#xD;
          -  History of grid/focal laser in the study eye&#xD;
&#xD;
          -  History of vitreal surgery&#xD;
&#xD;
          -  Previous treatment with triamcinolone acetonide in either eye&#xD;
&#xD;
          -  Previous use of bevacizumab, pegaptanib, or ranibizumab in either eye&#xD;
&#xD;
          -  Evidence of significant uncontrolled concomitant diseases such as cardiovascular&#xD;
             disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal&#xD;
             disorders&#xD;
&#xD;
          -  History of cerebrovascular accident within 1 year prior to Day 0&#xD;
&#xD;
          -  Inability to comply with study or follow-up procedures&#xD;
&#xD;
          -  Any cognitive defect as a result of mental disease, previous injury, or disease&#xD;
             process that may interfere with interpretation of study results&#xD;
&#xD;
          -  Visual acuity better than 20/40&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test) or lactation&#xD;
&#xD;
          -  Inadequate contraception in premenopausal women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence J Singerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Associates of Cleveland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Associates of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <last_update_submitted>March 16, 2011</last_update_submitted>
  <last_update_submitted_qc>March 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Lawrence J. Singerman, MD</name_title>
    <organization>Retina Associates of Cleveland</organization>
  </responsible_party>
  <keyword>Retinal vein occlusion</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Lucentis</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 19, 2019</submitted>
    <returned>October 10, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

